Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 (Becotatug Vedotin) ± bevacizumab in EGFR-positive platinum-resistant ovarian/peritoneal cancer
ChiCTR2600120503Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600120503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120503.